Spectrum Pharmaceuticals, Inc. Release: Levoleucovorin (FUSILEV(TM)) Listed in the NCCN Drugs & Biologics Compendium(TM) and National Comprehensive Cancer Network Updates Clinical Practice Guidelines in Oncology(TM)

IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI) today announced the listing of FUSILEV™ (levoleucovorin) for injection in the National Comprehensive Cancer Network® (NCCN) Drugs and Biologic Compendium™ to be used in combination with high-dose methotrexate for the treatment of bone cancer (osteosarcoma and dedifferentiated chrondrosarcoma).

Back to news